Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, Fourth Annual Evaluation - Day 1

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence

	5	4	3	2	1
Implement therapeutic strategies when treating hematologic malignancies.	Implement therapeutic strategies when treating hematologic malignancies. - 5	Implement therapeutic strategies when treating hematologic malignancies. - 4	Implement therapeutic strategies when treating hematologic malignancies. - 3	Implement therapeutic strategies when treating hematologic malignancies. - 2	Implement therapeutic strategies when treating hematologic malignancies. - 1

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Acute Myeloid Leukemia in 2023 - Richard Stone, M.D.	Acute Myeloid Leukemia in 2023 - Richard Stone, M.D. - 5	Acute Myeloid Leukemia in 2023 - Richard Stone, M.D. - 4	Acute Myeloid Leukemia in 2023 - Richard Stone, M.D. - 3	Acute Myeloid Leukemia in 2023 - Richard Stone, M.D. - 2	Acute Myeloid Leukemia in 2023 - Richard Stone, M.D. - 1
Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D.	Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D. - 5	Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D. - 4	Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D. - 3	Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D. - 2	Targeted Therapies in Acute Myeloid Leukemia - Eytan Stein, M.D. - 1
Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D.	Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D. - 5	Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D. - 4	Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D. - 3	Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D. - 2	Myelofibrosis: Current and Emerging Treatments - Raajit Rampal, M.D. - 1
Adult ALL: Frontline Treatment (R)Evolution! - Wendy Stock, M.D.	Adult ALL: Frontline Treatment (R)Evolution! - Wendy Stock, M.D. - 5	Adult ALL: Frontline Treatment (R)Evolution! - Wendy Stock, M.D. - 4	Adult ALL: Frontline Treatment (R)Evolution! - Wendy Stock, M.D. - 3	Adult ALL: Frontline Treatment (R)Evolution! - Wendy Stock, M.D. - 2	Adult ALL: Frontline Treatment (R)Evolution! - Wendy Stock, M.D. - 1
ALL: New Treatment Options for Relapsed Disease - Nitin Jain, M.D.	ALL: New Treatment Options for Relapsed Disease - Nitin Jain, M.D. - 5	ALL: New Treatment Options for Relapsed Disease - Nitin Jain, M.D. - 4	ALL: New Treatment Options for Relapsed Disease - Nitin Jain, M.D. - 3	ALL: New Treatment Options for Relapsed Disease - Nitin Jain, M.D. - 2	ALL: New Treatment Options for Relapsed Disease - Nitin Jain, M.D. - 1
Treatments for Multiple Myeloma - Paul Richardson, M.D.	Treatments for Multiple Myeloma - Paul Richardson, M.D. - 5	Treatments for Multiple Myeloma - Paul Richardson, M.D. - 4	Treatments for Multiple Myeloma - Paul Richardson, M.D. - 3	Treatments for Multiple Myeloma - Paul Richardson, M.D. - 2	Treatments for Multiple Myeloma - Paul Richardson, M.D. - 1
Targeted Therapies for Myeloma - Adam Cohen, M.D.	Targeted Therapies for Myeloma - Adam Cohen, M.D. - 5	Targeted Therapies for Myeloma - Adam Cohen, M.D. - 4	Targeted Therapies for Myeloma - Adam Cohen, M.D. - 3	Targeted Therapies for Myeloma - Adam Cohen, M.D. - 2	Targeted Therapies for Myeloma - Adam Cohen, M.D. - 1
Auto SCT vs CAR T in Multiple Myeloma - Gunjan Shah, M.D.	Auto SCT vs CAR T in Multiple Myeloma - Gunjan Shah, M.D. - 5	Auto SCT vs CAR T in Multiple Myeloma - Gunjan Shah, M.D. - 4	Auto SCT vs CAR T in Multiple Myeloma - Gunjan Shah, M.D. - 3	Auto SCT vs CAR T in Multiple Myeloma - Gunjan Shah, M.D. - 2	Auto SCT vs CAR T in Multiple Myeloma - Gunjan Shah, M.D. - 1
Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D.	Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D. - 5	Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D. - 4	Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D. - 3	Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D. - 2	Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D. - 1
Updates on Treatment Approaches for Primary (CNS) Lymphoma - Craig Sauter, M.D.	Updates on Treatment Approaches for Primary (CNS) Lymphoma - Craig Sauter, M.D. - 5	Updates on Treatment Approaches for Primary (CNS) Lymphoma - Craig Sauter, M.D. - 4	Updates on Treatment Approaches for Primary (CNS) Lymphoma - Craig Sauter, M.D. - 3	Updates on Treatment Approaches for Primary (CNS) Lymphoma - Craig Sauter, M.D. - 2	Updates on Treatment Approaches for Primary (CNS) Lymphoma - Craig Sauter, M.D. - 1
Updates on Management of Early and Advanced Stage Disease of Hodgkin's Disease - Alison Moskowitz, M.D.	Updates on Management of Early and Advanced Stage Disease of Hodgkin's Disease - Alison Moskowitz, M.D. - 5	Updates on Management of Early and Advanced Stage Disease of Hodgkin's Disease - Alison Moskowitz, M.D. - 4	Updates on Management of Early and Advanced Stage Disease of Hodgkin's Disease - Alison Moskowitz, M.D. - 3	Updates on Management of Early and Advanced Stage Disease of Hodgkin's Disease - Alison Moskowitz, M.D. - 2	Updates on Management of Early and Advanced Stage Disease of Hodgkin's Disease - Alison Moskowitz, M.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will provide an update of new molecular and immunological treatments being developed.

I will review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.

I will discuss the rational for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia.

I will discuss the evolving therapeutic strategies in the treatment of hematologic malignancies.

Not applicable to my practice.

I do not agree with the recommendations presented.

I am retired.

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name *

Attestation *

Choose 1 option

I attest that I have participated in this live symposium in its entirety.

I attest that I have participated in _____ hours of instruction during this live symposium.

hours attestation *

Hours attended

You are here

Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, Fourth Annual Evaluation - Day 1